Patents
Literature
Patsnap Eureka AI that helps you search prior art, draft patents, and assess FTO risks, powered by patent and scientific literature data.

274 results about "Macrocycle Compounds" patented technology

Macrocyclic compound. An organic compound containing a large ring, that is, a closed chain of 12 or more carbon atoms; examples include crown ethers, cryptands, spherands, carcerands, cyclodextrins, cyclophanes, and calixarenes. Also known as macrocycle.

Ras inhibitors

The disclosure features macrocyclic compounds, and pharmaceutical compositions and protein complexes thereof, capable of inhibiting Ras proteins, and their uses in the treatment of cancers.
Owner:REVOLUTION MEDICINES INC

Macrocyclic compounds as modulators of KRAS and uses thereof

Disclosed herein are compounds useful for the inhibition of KRAS G12D, G12V, G12A, G12S, G12R, G13D, Q61H, Q61L, Q61R or G12C. The compounds have a general Formula (I): or pharmaceutically acceptable salts thereof, wherein the variables of Formula (I) are as defined herein. Also provided herein are pharmaceutical compositions comprising the compounds, uses of the compounds, and compositions for treatment of, for example, a KRAS G12D, G12V, G12A, G12S, G12R, G13D, Q61H, Q61L, Q61R or G12C disorder.
Owner:AMGEN INC

Ras inhibitors

The disclosure features macrocyclic compounds, and pharmaceutical compositions and protein complexes thereof, capable of inhibiting Ras proteins, and their uses in the treatment of cancers.
Owner:REVOLUTION MEDICINES INC

Ras inhibitors

The disclosure features macrocyclic compounds, and pharmaceutical compositions and protein complexes thereof, capable of inhibiting Ras proteins, and their uses in the treatment of cancers.
Owner:REVOLUTION MEDICINES INC

Solid forms of macrocyclic compounds and uses thereof

The disclosure provides solid forms of Compound A, as described herein. The disclosure also provides pharmaceutical compositions comprising the disclosed solid forms and methods of using the disclosed solid forms and pharmaceutical compositions (e.g., to treat cancer).
Owner:AMGEN INC

Macrocyclic compounds as modulators of KRAS and uses thereof

Disclosed herein are compounds useful for the inhibition of KRAS G12D, G12V, G12A, G12S, G12R, G13D, Q61H, Q61L, Q61R or G12C. The compounds have a general Formula (I): or pharmaceutically acceptable salts thereof, wherein the variables of Formula (I) are as defined herein. Also provided herein are pharmaceutical compositions comprising the compounds, uses of the compounds, and compositions for treatment of, for example, a KRAS G12D, G12V, G12A, G12S, G12R, G13D, Q61H, Q61L, Q61R or G12C disorder
Owner:AMGEN INC

Composite separation membrane for enriching < 6 > Li isotope and application

The invention discloses a composite separation membrane for enriching < 6 > Li isotope and application. The composite separation membrane comprises a functional membrane and at least one supporting membrane; the functional film comprises a plurality of pore channels penetrating through the first surface and the second surface of the functional film, and the pore channel diameter of each pore channel is 0.4-0.7 nm; a lithium ion trapping functional group or a macrocyclic compound and a derivative thereof are modified at an inlet of the first surface of the pore channel. The strength of the lithium isotope separation effect depends on the diameter of a pore channel of the composite separation membrane and functional groups modified at an inlet, does not change along with the migration time and the lithium ion migration proportion, and has long-term continuous stability.
Owner:QINGHAI INST OF SALT LAKES OF CHINESE ACAD OF SCI

Macrocyclic compounds as modulators of KRAS and uses thereof

Disclosed herein are compounds useful for the inhibition of KRAS G12D, G12V, G12A, G12S, G12R, G13D, Q61H, Q61L, Q61R or G12C. The compounds have a general Formula (I) or pharmaceutically acceptable salts thereof, wherein the variables of Formula (I) are as defined herein. Also provided herein are pharmaceutical compositions comprising the compounds, uses of the compounds, and compositions for treatment of, for example, a KRAS G12D, G12V, G12A, G12S, G12R, G13D, Q61H, Q61L, Q61R or G12C disorder.
Owner:AMGEN INC

Ras inhibitors

The disclosure features macrocyclic compounds, and pharmaceutical compositions and protein complexes thereof, capable of inhibiting Ras proteins, and their uses in the treatment of cancers.
Owner:REVOLUTION MEDICINES INC

Ras inhibitors

The disclosure features macrocyclic compounds, and pharmaceutical compositions and protein complexes thereof, capable of inhibiting Ras proteins, and their uses in the treatment of cancers.
Owner:REVOLUTION MEDICINES INC

Ras inhibitors

The disclosure features macrocyclic compounds, and pharmaceutical compositions and protein complexes thereof, capable of inhibiting Ras proteins, and their uses in the treatment of cancers.
Owner:REVOLUTION MEDICINES INC

Novel liver and gall specificity contrast agent

The invention provides a novel macrocyclic compound, a gadolinium chelate thereof, a method for preparing the compound and application of the compound as a magnetic resonance contrast agent. The compound has pertinence on magnetic resonance detection of liver focal lesions and can be used for liver specific imaging.
Owner:CHENGDU BRILLIANT PHARMA CO LTD +1

Ras inhibitors

The disclosure features macrocyclic compounds, and pharmaceutical compositions and protein complexes thereof, capable of inhibiting Ras proteins, and their uses in the treatment of cancers.
Owner:REVOLUTION MEDICINES INC

Ras inhibitors

The disclosure features macrocyclic compounds, and pharmaceutical compositions and protein complexes thereof, capable of inhibiting Ras proteins, and their uses in the treatment of cancers.
Owner:REVOLUTION MEDICINES INC

Ras inhibitors

The disclosure features macrocyclic compounds, and pharmaceutical compositions and protein complexes thereof, capable of inhibiting Ras proteins, and their uses in the treatment of cancers.
Owner:REVOLUTION MEDICINES INC

Ras inhibitors

The disclosure features macrocyclic compounds, and pharmaceutical compositions and protein complexes thereof, capable of inhibiting Ras proteins, and their uses in the treatment of cancers.
Owner:REVOLUTION MEDICINES INC

Ras inhibitors

The disclosure features macrocyclic compounds, and pharmaceutical compositions and protein complexes thereof, capable of inhibiting Ras proteins, and their uses in the treatment of cancers.
Owner:REVOLUTION MEDICINES INC